Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
91 hedge funds and large institutions have $93.6M invested in Y-mAbs Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 33 reducing their positions, and 29 closing their positions.
9% less funds holding
Funds holding: 100 → 91 (-9)
9.68% less ownership
Funds ownership: 53.89% → 44.21% (-9.7%)
24% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 33
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
69% less capital invested
Capital invested by funds: $303M → $93.6M (-$210M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.03M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.32M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.49M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.27M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.1M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$14.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.9M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$6.4M |
YMAB Hedge Fund Activity: Q4 2022 in Review
91 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2022, worth a combined $93.6M — down 69% from $303M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of YMAB and 20 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 25 added.
The largest buyer was Millennium Management, adding an estimated $8.03M. The largest seller was Wellington Management Group, exiting entirely with an estimated $28.1M sold.
- 91 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2022, down from 100 in Q3 2022.
- Funds reported $93.6M of Y-mAbs Therapeutics stock for Q4 2022, down 69% quarter-over-quarter.
- 20 funds opened new Y-mAbs Therapeutics positions in Q4 2022 and 29 closed out, a net change of -9 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $8.03M added.
- The largest Y-mAbs Therapeutics seller in Q4 2022 was Wellington Management Group, an estimated $28.1M sold.
Based on aggregated 13F filings for Q4 2022.